Ruxolitinib (Rux)

DRUG2 trials

Sponsors

Novartis Pharmaceuticals, Incyte Corporation

Conditions

Corticosteroid Refractory Acute Graft vs Host DiseaseGraft-versus-host Disease (GVHD)

Phase 3

Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation

CompletedNCT02913261

Novartis PharmaceuticalsCorticosteroid Refractory Acute Graft vs Host Disease

Start: 2017-03-10End: 2021-04-23Updated: 2023-02-08

A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)

RecruitingNCT06615050

Incyte CorporationGraft-versus-host Disease (GVHD)

Start: 2025-04-02End: 2031-01-17Target: 572Updated: 2025-12-16

Related Papers

Impact of concomitant azoles on ruxolitinib treatment in patients with GVHD: post hoc analyses of REACH2 and REACH3

Blood Advances2025-06-05

Prognostic Value of Blood Biomarkers in Steroid-Refractory/Dependent Acute Graft-vs-Host Disease: A REACH2 Analysis

Blood2023-02-249 citations

Early Versus Late Treatment with Ruxolitinib in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease: A Post Hoc Analysis from the Randomized Phase 3 REACH2 Study

Blood2022-11-15

Biomarker Analysis in Patients (pts) with Steroid-Refractory Acute Graft-Vs-Host Disease (aGVHD) Treated with Ruxolitinib (RUX) or Best Available Therapy (BAT) in the Randomized, Phase 3 REACH2 Study

Blood2020-11-052 citations

Safety Analysis of Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients (pts) with Steroid-Refractory (SR) Acute Graft-Vs-Host Disease (aGVHD) in the Randomized Phase 3 REACH2 Study

Blood2020-11-04

Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease

New England Journal of Medicine2020-04-22813 citations

Ruxolitinib for the treatment of graft-versus-host disease.

2020-04-0119 citations

Ruxolitinib, a JAK1/JAK2 Selective Inhibitor Is Highly Efficacious in Corticosteroid Untreated and Refractory MHC-Mismatched Mouse Model of Acute GvHD

Blood2018-11-294 citations

Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)

BMC Cancer2018-11-1954 citations

Ruxolitinib for the Treatment of Patients with Steroid-Refractory GVHD: An Introduction to the REACH Trials

Immunotherapy2018-01-1093 citations